Cargando…
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
BACKGROUND: YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model. The study was conducted to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic variables, and antitumor activity in advanced solid malignancies. METHODS: This...
Autores principales: | Li, Jin, Zhao, Xinmin, Chen, Lei, Guo, Haiyi, Lv, Fangfang, Jia, Ka, Yv, Ke, Wang, Fengqing, Li, Chuan, Qian, Jun, Zheng, Chunlei, Zuo, Yunxia |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984425/ https://www.ncbi.nlm.nih.gov/pubmed/20923544 http://dx.doi.org/10.1186/1471-2407-10-529 |
Ejemplares similares
-
DKK4 enhances resistance to chemotherapeutics 5-Fu and YN968D1 in colorectal cancer cells
por: He, Shengli, et al.
Publicado: (2017) -
The pattern of gynecological malignancies in 968 cases from Pakistan
por: Jamal, Shahid, et al.
Publicado: (2006) -
Evaluation of 968 children with corrosive substance ingestion
por: Karaman, İbrahim, et al.
Publicado: (2015) -
Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non‐small cell lung cancer after second‐line chemotherapy treatment: A retrospective study
por: Zhang, Di, et al.
Publicado: (2018) -
A compilation of YN reactions
por: Barash-Schmidt, Naomi, et al.
Publicado: (1970)